Mustang Bio Inc. (Nasdaq: MBIO)

https://www.mustangbio.com

LinkedIn: https://www.linkedin.com/company/mustangbio

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR T therapies across multiple cancers, as well as a lentiviral gene therapy for XSCID. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). *

	Start	2020-10-06 existent
	Industry	gene therapy
	Industry 2	CAR T-cell therapy product
	Person	Litchman, Manuel (Mustang Bio 201704– CEO before Arvinas + Novartis Pharmaceuticals Corp)

	Street	377 Plantation Street
	City	01605 Worcester, MA
	Tel	+1-781-652-4500
		Address record changed: 2024-01-05

Basic data	Employees	n. a.

		* Document for »About Section«: Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried.

		Record changed: 2023-07-10

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Mustang Bio Inc. (Nasdaq: MBIO)

[1] Sirion Biotech GmbH. (10/6/20). "Press Release: Mustang Bio Licenses LentiBOOST Technology from Sirion Biotech for the Development of MB-207 Lentiviral Gene Therapy". Worcester, MA & Martinsried....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]